Geode Capital Management LLC Has $10.50 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Geode Capital Management LLC reduced its position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 6.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 953,167 shares of the biotechnology company's stock after selling 60,423 shares during the quarter. Geode Capital Management LLC owned 1.69% of Astria Therapeutics worth $10,496,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Barclays PLC grew its holdings in shares of Astria Therapeutics by 70.5% during the 3rd quarter. Barclays PLC now owns 92,651 shares of the biotechnology company's stock valued at $1,020,000 after acquiring an additional 38,321 shares in the last quarter. Wellington Management Group LLP boosted its position in Astria Therapeutics by 8.7% during the third quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company's stock worth $1,624,000 after purchasing an additional 11,763 shares during the period. RA Capital Management L.P. raised its position in shares of Astria Therapeutics by 1.2% in the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company's stock valued at $56,208,000 after purchasing an additional 61,457 shares during the period. Redmile Group LLC acquired a new position in Astria Therapeutics in the 3rd quarter valued at $3,423,000. Finally, Patient Square Capital LP bought a new stake in Astria Therapeutics during the third quarter valued at about $434,000. Institutional investors and hedge funds own 98.98% of the company's stock.

Astria Therapeutics Price Performance

Shares of ATXS traded up $0.06 during trading hours on Wednesday, hitting $8.94. The stock had a trading volume of 526,247 shares, compared to its average volume of 584,853. The stock has a market capitalization of $504.52 million, a price-to-earnings ratio of -4.28 and a beta of 0.67. Astria Therapeutics, Inc. has a 52 week low of $6.58 and a 52 week high of $16.90. The company's fifty day moving average is $10.35 and its two-hundred day moving average is $10.73.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Oppenheimer boosted their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a research report on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a research report on Tuesday, December 10th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $25.60.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.